

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024714 A1

- (51) International Patent Classification⁷: **C07D 401/12**,
A61K 31/47, A61P 25/00
- (21) International Application Number:
PCT/EP2003/010007
- (22) International Filing Date:
9 September 2003 (09.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0220953.4 10 September 2002 (10.09.2002) GB
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **VEENSTRA, Siem, Jacob** [NL/DE]; Rebweg 28, 79540 Lörrach (DE).
- (74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AROYL-PIPERIDINE DERIVATIVES




(II)

(57) Abstract: The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylamino)-piperidines of the formula ...wherein Y and R each are as defined above and the ring A is unsubstituted or mono- or polysubstituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl; and the salts thereof, to the use thereof, to processes for the preparation thereof and to pharmaceutical compositions comprising a compound according to the invention.

WO 2004/024714 A1

Aroyl-piperidine derivatives

The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloyl-amino)-piperidines of the formula



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)- and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, provided that when R is OH and Y is =N- the ring A is not unsubstituted; to the use thereof; to processes for the preparation thereof and to pharmaceutical compositions comprising a compound according to the invention.

Since the compounds according to the invention have at least two optically active carbon atoms they may accordingly be present in the form of stereoisomers, stereoisomeric mixtures and in the form of the (substantially) pure diastereoisomers. The present invention relates also to corresponding stereoisomers.

Preference is given to compounds of formula I wherein the ring A is substituted.

Unless otherwise defined, the general terms used hereinbefore and hereinafter have the meanings given below.

The term "lower" denotes that groups and compounds so defined each have from 1 up to and including 7, preferably from 1 up to and including 4, carbon atoms.

Lower alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl or a corresponding pentyl, hexyl or heptyl radical. C₁-C₄alkyl is preferred.

Lower alkoxy is, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy or a corresponding pentyloxy, hexyloxy or heptyloxy radical C₁-C₄alkoxy is preferred.

Halogen is especially halogen having an atomic number of up to and including 35, i.e. fluorine, chlorine or bromine, and also includes iodine. Chlorine is preferred.

Substance P is a naturally occurring undecapeptide of the tachykinin family. It is produced in mammals and acts pharmacologically as a neuropeptide. Substance P plays an important role in various disorders, for example in the case of painful conditions, in migraines and in certain disorders of the central nervous system, such as anxiety states, vomiting, schizophrenia and depression, and in certain motor disorders, such as Parkinson's disease, but also in inflammatory diseases, such as rheumatoid arthritis iritis and conjunctivitis, in diseases of the respiratory organs, such as asthma and chronic bronchitis, in diseases of the gastrointestinal system, such as ulcerative colitis and Crohn's disease, and in hypertension.

A great deal of work is being done to advance the development of the field of substance-P-antagonists and, for example, to find suitable substance-P-antagonists having a broad spectrum of action that exhibit outstanding *in vivo* activity and increased bioavailability as well as improved chemical stability.

Extensive pharmacological studies have shown that the compounds according to the invention antagonise substance P to an especially preferred extent and thus inhibit the symptoms induced by substance P.

The substance-P-antagonising effects can be demonstrated - as shown below - using test methods known to the person skilled in the art. Such effects are observed both *in vitro* and *in vivo*. For example, the substance-P-induced formation of phosphoinositol in human astrocytoma cells is antagonised *in vitro* by the compounds of formula I and IA. IC₅₀ values of from approximately 1 nmol are found. A suitable test model for the detection of that

inhibition is, for example, the test method of Lee, C.M. *et al.*, as described in *J.Neurochem.* 59, 406-414 (1992).

In addition, the binding of ^3H -substance P to bovine retina in the radio receptor assay according to H. Bittiger, Ciba Foundation Symposium 91, 196-199 (1982) is inhibited with IC_{50} values of from approximately 1 nmol. For example, the following *in vitro* values of about 10 nM were obtained for the target compounds of Examples 1 and 2.

A change in behaviour is produced in gerbils by i.c.v. administration of substance P methyl ester. That effect can be inhibited *in vivo* after peroral administration of compounds of formulae I and IA and the salts thereof. A.Vassout *et al.* which was presented at the "Substance P and Related Peptides: Cellular and Molecular Physiology" Congress in Worcester, Mass., in 1990. In that method, ED_{50} values of from approximately 0.1 mg/kg p.o. are obtained, demonstrating their usefulness in the treatment of disorders of the central nervous system.

In vivo, using the experimental procedure of Lundberg *et al.*, Proc. Nat. Acad. Sci. (USA) 80, 1120-1124, the compounds of formulae I and IA and the salts thereof inhibit vagally induced bronchospasms in guinea pigs at a dose of from approximately 1.0 mg/kg i.v., which demonstrates their suitability for the treatment of asthma.


The substance-P-antagonists of formulae I and IA prepared in accordance with the invention and the pharmaceutically acceptable salts thereof are accordingly outstandingly suitable for the therapeutic treatment of the pathological symptoms listed hereinbefore.

The invention relates also to a method of treating disorders induced by substance P by the administration of a therapeutically effective amount of a compound of formula I or IA.

The present invention relates also to the use of a compound of formula I or IA in the preparation of medicaments for the treatment of disorders induced by substance P.

The invention relates also to the use of compounds of formula I or IA as biochemical tools, for example for the identification and, possibly, the profiling of further potent substance-P-antagonists.

The invention relates especially to compounds of formula IA




wherein Y and R are as defined above and Z is hydrogen, halogen or nitro, provided that when R is OH and Y is =N- Z is not H.

The invention relates above all to compounds of formula IA wherein Y and R are defined above and Z is halogen, such as chlorine.

The invention relates specifically to the compounds of formula I mentioned in the Examples.

The invention relates also to processes for the preparation of the compounds according to the invention. Those processes comprise oxidising a compound of formula II



and, if desired, separating a mixture of isomers obtainable by the process and isolating the desired isomer.

The compound of formula II may be oxidised to give a compound of formula I; for instance, with 3-chloroperbenzoic acid at room temperature.

Alternatively compounds of formula I in which R is OH and Y is =N- may be prepared by linking of the corresponding [(2R, 4S)-4-Amino-2-(4-benzyl-piperidin-1-yl)]-(3,5-bis(trifluormethyl-phenyl)-methanone with 2-hydroxyquinoline-4-carboxylic acid; for instance as hereinafter described in Example 2.

The invention is illustrated especially by the Examples and relates also to the novel compounds mentioned in the Examples and to the processes for the preparation thereof.

The compounds of formula I and IA, may also be obtained in the form of hydrates or may include the solvent used for crystallisation.

Resulting mixtures of diastereoisomers and mixtures of racemates can be separated in known manner into the pure diastereoisomers or racemates on the basis of the physico-chemical differences between the constituents, for example by chromatography and/or fractional crystallisation.


Resulting racemates can also be separated into the optical antipodes by known methods, for example by recrystallisation from an optically active solvent, with the aid of microorganisms or by reaction of the resulting diastereoisomeric mixture or racemate with an optically active auxiliary compound, for example according to the acidic, basic or functionally modifiable groups present in compounds of formulae I and IA with an optically active acid, base or an optically active alcohol, into mixtures of diastereoisomeric salts or functional derivatives, such as esters, and separation thereof into the diastereoisomers from which the desired enantiomer can be freed in the appropriate customary manner. Examples of suitable bases, acids and alcohols are optically active alkaloid bases, such as strychnine, cinchonine or brucine, or D- or L-(1-phenyl)ethylamine, 3-pipecoline, ephedrine, amphetamine and similar synthetically obtainable bases, optically active carboxylic or sulfonic acids, such as quinic acid or D- or L-tartaric acid, D- or L-di-o-toluyltartaric acid, D- or L-malic acid, D- or L-mandelic acid, or D- or L-camphorsulfonic acid, or optically active alcohols, such as borneol or D- or L-(1-phenyl)ethanol.

The novel compounds of formulae I and IA can be used, for example, in the form of pharmaceutical compositions that comprise a therapeutically effective amount of the active ingredient, optionally together with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers that are suitable for enteral, for example oral, or parenteral administration. There are used, for example, tablets or gelatin capsules that comprise the active ingredient together with diluents, for example lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or lubricants, for example silica, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Tablets can also comprise binders, for example magnesium aluminium silicate, starches, such as corn, wheat, rice or arrowroot starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, for example sodium alginate, and/or effervescent mixtures, or absorbents, colourings, flavourings and sweeteners. The novel compounds of formulae I and IA can also be used in the form of parenterally administrable compositions or in the form of infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspensions which, for example in the case of lyophilised compositions that comprise the active ingredient on its own or together with a carrier, for example mannitol, can be prepared before use. The pharmaceutical compositions may be sterilised and/or may comprise excipients, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers. The pharmaceutical compositions in question, which, if desired, may comprise further pharmacologically active substances, are prepared in a manner known *per se*, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes, and comprise from approximately 0.1 % to 100 %, especially from approximately 1 % to approximately 50 %, in the case of lyophilisates up to approximately 100 %, active ingredient.

The invention relates also to the use of the compounds of formulae I and IA, preferably in the form of pharmaceutical compositions. The dose can depend on various factors, such as the mode of administration, species, age and/or individual condition. The daily doses to be administered are, in the case of oral administration, from approximately 0.25 to approximately 10 mg/kg, and in the case of warm-blooded animals having a body weight of approximately 70 kg, they are preferably from approximately 20 mg to approximately 500 mg.

The following Examples illustrate the invention; temperatures are given in degrees Celsius and pressures in mbar.


Example 1: 1-Oxy-quinoline-4-carboxylic acid [(2R,4S)-1-(3,5-bis-trifluoromethyl-benzoyl)-2-(4-chloro-benzyl)-piperidin-4-yl]-amide



To a solution of 6.0 g (9.68 mMol) quinoline-4-carboxylic acid [(2R,4S)-1-(3,5-bis-trifluoromethyl-benzoyl)-2-(4-chloro-benzyl)-piperidin-4-yl]-amide (Synthesis described in EP 707 006 A) in 60 ml of CH₂Cl₂ were added 2.07 g (10.2 mMol) of 3-chloroperbenzoic acid (85%) at room temperature with stirring. After the mixture became homogeneous it was left at room temperature for 18 hrs. The mixture was washed successively with 5% aqueous NaHSO₃ and 10% aqueous NaHCO₃. The organic phase was dried with K₂CO₃ and concentrated in vacuo. The crude product was recrystallized from MeOH/H₂O. Yield 4.9 g white crystals. Mp. 223-225°C

MS(ES⁺): [M+1]⁺= 636 and [M+23]⁺= 658.

Example 2: 2-Hydroxy-quinoline-4-carboxylic acid [(2R,4S)-1-(3,5-bis-trifluoromethyl-benzoyl)-2-(4-chloro-benzyl)-piperidin-4-yl]-amide



To a stirred mixture of 2.52 g (13.32 mMol) 2-hydroxyquinoline-4-carboxylic acid, 2.7 g (15.98 mMol) HOBt (80%), 3.7 ml (26.64 mMol) triethylamine and 3.8 g (18.64 mMol) DCC in 50 ml of CH_2Cl_2 were added at room temperature 12.3 g (13.32 mMol) [(2R,4S)-4-Amino-2-(4-chloro-benzyl)-piperidin-1-yl]-(3,5-bis-trifluoromethyl-phenyl)-methanone (synthesis described in EP 707006A). After 18 h the reaction mixture was diluted with 500 ml THF and filtered through a fritted glass funnel with suction. The filtrate was further diluted with ethyl acetate and washed three times with brine. The organic phase was dried with Na_2SO_4 and concentrated in vacuo. The product was purified by chromatography on silica gel using successively EtOAc/ CH_2Cl_2 (2:1), EtOAc and EtOAc/THF (3:1) as eluents. The product was suspended in hexane and stirred at 60°C overnight. The mixture was filtered and dried and a yield of 6.2 g of white crystals. M.p.222-224°C.

$[\text{M}+1]^+ = 636$ and $[\text{M}+23]^+ = 658$

Example 3: Tablets, each comprising 50 mg of (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]quinoline-N-oxide-4-carboxamide can be prepared as follows:

Composition (10 000 tablets)

active ingredient	500.0 g
lactose	500.0 g
potato starch	352.0 g
gelatin	8.0 g
talc	60.0 g
magnesium stearate	10.0 g

- 9 -

silicon dioxide (highly dispersed)	20.0 g
ethanol	q.s.

The active ingredient is mixed with the lactose and 292 g of potato starch and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a sieve. After drying, the remainder of the potato starch, the magnesium stearate, the talc and the silicon dioxide are mixed in and the mixture is compressed to form tablets, each weighing 145.0 mg and comprising 50.0 mg of active ingredient; the tablets may, if desired, be provided with breaking notches for finer adaptation of the dose.

Example 4: Film-coated tablets, each comprising 100 mg of (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-3-hydroxy-quinoline-4-carboxamide can be prepared as follows:

Composition (for 1000 film-coated tablets)

active ingredient	100.0 g
lactose	100.0 g
corn starch	70.0 g
talc	8.5 g
calcium stearate	1.5 g
hydroxypropylmethylcellulose	2.36 g
shellac	0.64 g
water	q.s.
methylene chloride	q.s.

The active ingredient, the lactose and 40 g of the corn starch are mixed and moistened with a paste prepared from 15 g of corn starch and water (with heating) and granulated. The granules are dried, the remainder of the corn starch, the talcum and the calcium stearate are added and mixed with the granules. The mixture is compressed to form tablets (weight: 280 mg) which are then film-coated with a solution of the hydroxypropylmethylcellulose and the shellac in methylene chloride; final weight of the film-coated tablet: 283 mg.

Example 5: Hard gelatin capsules, comprising 100 mg of active ingredient, for example (2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-quinoline-N-oxide-4-carboxamide or a salt, for example the hydrochloride, thereof, can be prepared, for example, as follows:


Composition (for 1000 capsules)

active ingredient	100.0 g
lactose	250.0 g
microcrystalline cellulose	30.0 g
sodium lauryl sulfate	2.0 g
magnesium stearate	8.0 g

The sodium lauryl sulfate is added to the lyophilised active ingredient through a sieve of 0.2 mm mesh size. The two components are intimately mixed. Then first the lactose is added through a sieve of 0.6 mm mesh size and then the microcrystalline cellulose is added through a sieve of 0.9 mm mesh size. The mixture is then intimately mixed again for 10 minutes. Finally the magnesium stearate is added through a sieve of 0.8 mm mesh size. After mixing for a further 3 minutes, size 0 hard gelatin capsules are each filled with 390 mg of the resulting formulation.


CLAIMS:

1. A compound of the formula



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)- and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, provided that when R is OH and Y is =N- the ring A is not unsubstituted.

2. A compound according to claim 1 of formula IA



wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is hydrogen, halogen or nitro, provided that when R is OH and Y is =N- Z is not H.

3. A compound according to claim 2 of formula IA, wherein Y is =N- or =N(O)-, R is OH when Y is =N- and R is H when Y is =N(O)-, and Z is halogen.

4. A compound selected from:

(2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-quinoline-N-oxide-4-carboxamide or a salt thereof, and


(2R,4S)-N-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-piperidin-4-yl]-3-hydroxy-quinoline-4-carboxamide.

5. A compound according to any one of claims 1 to 4 for use in a method for the treatment of the human or animal body.

6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4.

7. The use of a compound according to any one of claims 1 to 4 in the preparation of a pharmaceutical composition for the treatment of disorders induced by substance P.

8. A process for the preparation of a compound according to any one of claims 1 to 4, which comprises oxidising a compound of formula II



and if desired, (separating a mixture of isomers obtainable by the process and isolating the desired isomer

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/10007

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 A61K31/47 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 707 006 A (CIBA GEIGY AG) 17 April 1996 (1996-04-17) claims; examples 1,3 ----	1-8
Y	WO 99 61025 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); LANG STEFFEN (CH);) 2 December 1999 (1999-12-02) claims 5,6 ----	1-8
Y	WO 97 45119 A (CIBA GEIGY AG ;HAUSER KATHLEEN (CH); STRUCK MICHAEL (DE); VASSOUT) 4 December 1997 (1997-12-04) claim 11 ----	1-8
Y	EP 0 739 892 A (CIBA GEIGY AG) 30 October 1996 (1996-10-30) claims; examples -----	1-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 December 2003

Date of mailing of the international search report

19/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10007

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0707006	A	17-04-1996	AT 178602 T	15-04-1999
			AU 705851 B2	03-06-1999
			AU 3317495 A	26-04-1996
			BR 1100457 A3	30-04-2002
			CA 2160444 A1	15-04-1996
			CN 1133839 A , B	23-10-1996
			DE 59505575 D1	12-05-1999
			DK 707006 T3	18-10-1999
			EP 0707006 A1	17-04-1996
			ES 2132580 T3	16-08-1999
			FI 954829 A	15-04-1996
			GR 3030515 T3	29-10-1999
			HU 74103 A2	28-11-1996
			IL 115572 A	20-05-2001
			JP 3022951 B2	21-03-2000
			JP 8176145 A	09-07-1996
			NO 954067 A	15-04-1996
			NZ 280212 A	26-10-2001
			RU 2158731 C2	10-11-2000
			TW 397825 B	11-07-2000
			US 5965562 A	12-10-1999
			ZA 9508647 A	15-04-1996
WO 9961025	A	02-12-1999	AU 755134 B2	05-12-2002
			AU 4500899 A	13-12-1999
			BE 1012143 A5	02-05-2000
			BR 9910696 A	30-01-2001
			CA 2333154 A1	02-12-1999
			CN 1303285 T	11-07-2001
			DE 19983247 T0	31-05-2001
			WO 9961025 A1	02-12-1999
			EP 1082119 A1	14-03-2001
			FR 2779145 A1	03-12-1999
			GB 2353473 A	28-02-2001
			HU 0102202 A2	28-11-2001
			IT MI991164 A1	27-11-2000
			JP 2002516280 T	04-06-2002
			NO 20005920 A	25-01-2001
			NZ 508325 A	30-06-2003
			PL 344245 A1	08-10-2001
			SK 17752000 A3	10-05-2001
			TR 200003502 T2	20-04-2001
			TW 537894 B	21-06-2003
			US 2002156099 A1	24-10-2002
			US 2003152626 A1	14-08-2003
			ZA 200006597 A	14-12-2001
WO 9745119	A	04-12-1997	AU 2898297 A	05-01-1998
			WO 9745119 A1	04-12-1997
			ID 18679 A	30-04-1998
EP 0739892	A	30-10-1996	AT 224891 T	15-10-2002
			AU 714523 B2	06-01-2000
			AU 5080596 A	07-11-1996
			BR 9602025 A	06-10-1998
			CA 2174707 A1	25-10-1996
			CN 1141921 A , B	05-02-1997
			DE 59609707 D1	31-10-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0739892 A		DK 739892 T3	20-01-2003
		EP 0739892 A2	30-10-1996
		ES 2183923 T3	01-04-2003
		HU 9601062 A2	28-10-1997
		IL 117989 A	31-01-2000
		JP 3068458 B2	24-07-2000
		JP 9003066 A	07-01-1997
		NO 961616 A	25-10-1996
		NZ 286422 A	26-01-1998
		PT 739892 T	31-01-2003
		RU 2156250 C2	20-09-2000
		TW 475930 B	11-02-2002
		US 5604247 A	18-02-1997
		ZA 9603211 A	24-10-1996